Bradmer Pharmaceuticals Inc. (TSX: BMR) has closed its private placement under which it has issued 8,369,947 common shares at a price of $0.095 per share which resulted in gross proceeds of $795,000.
Xplosive Stocks, an online financial publication, provides investors timely stock market information.
Sign Up Today for our Free Stock Newsletter
The company will mainly use their proceeds for working capital and general corporate purposes. Completion of the financing is subject to the final approval of the Toronto Stock Exchange.
Bradmer Pharmaceuticals, Inc. is dedicated to the development and commercialization of new and innovative cancer therapies. The Company’s first product candidate, Neuradiab, invented by world-class scientists at Duke University, represents a significant advance in the treatment of certain brain cancers.
Sign up for the free Xplosive Stocks newsletter. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by Xplosive Stocks can sign up for free by visiting our website.
About Us
Xplosive Stock is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We focus on Xplosive Stocks and track small cap companies that are on the brink of a financial breakout. To feature a company on our website please contact us at the email listed below.
Please click here to read the full disclaimer.
